CDT Equity's Sarborg Files New Cystic Fibrosis Patent

CDT Equity Inc. announced that Sarborg Limited, in which CDT holds a 20% stake, has filed a new Substance of Matter (SOM) patent covering two established compounds in the cystic fibrosis market. Sarborg developed the patent using its proprietary Signature Agent and Multi-Agent platform, achieving filing in under three weeks. CDT views this as strong validation of Sarborg's platform capabilities and its commercial potential, intending to leverage this approach to expand its intellectual property and explore combination therapies with its own assets.